Journal of Diabetes and Its Complications
Volume 19, Issue 1 , Pages 18-25 , January 2005

Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: Associations with microvascular disease complications in the DCCT/EDIC cohort

  • DCCT/EDIC Research Group
    • ,
  • Richard L. Klein

      Affiliations

    • Corresponding Author InformationCorresponding author. Department of Medicine, Division of Endocrinology, Metabolism and Medical Genetics, Medical University of South Carolina, 114 Doughty Street, P.O. Box 250770, Charleston, SC 29425, USA. Tel.: +1-843-789-6801; fax: +1-843-876-5133.
    • Department of Medicine, Division of Endocrinology, Metabolism, and Medical Genetics, Medical University of South Carolina, Charleston, SC, USA
    • Research Service, Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, SC, USA
    • ,
  • M.Brent McHenry

      Affiliations

    • Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Kerry H. Lok

      Affiliations

    • Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA
    • ,
  • Steven J. Hunter

      Affiliations

    • Department of Medicine, Division of Endocrinology, Metabolism, and Medical Genetics, Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Ngoc-Anh Le

      Affiliations

    • Division of Atherosclerosis and Lipid Metabolism, Emory University, Atlanta, GA, USA
    • ,
  • Alicia J. Jenkins

      Affiliations

    • Department of Medicine, Division of Endocrinology, Metabolism, and Medical Genetics, Medical University of South Carolina, Charleston, SC, USA
    • Department of Medicine, St. Vincent's Hospital, University of Melbourne, Fitzroy, Australia
    • Section of Endocrinology Diabetes and Hypertension, Oklahoma University Health Sciences Foundation, Oklahoma City, OK, USA
    • ,
  • Deyi Zheng

      Affiliations

    • Department of Biometry and Epidemiology, Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Andrea Semler

      Affiliations

    • Department of Medicine, Division of Endocrinology, Metabolism, and Medical Genetics, Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Grier Page

      Affiliations

    • Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA
    • ,
  • W.Virgil Brown

      Affiliations

    • Division of Atherosclerosis and Lipid Metabolism, Emory University, Atlanta, GA, USA
    • ,
  • Timothy J. Lyons

      Affiliations

    • Section of Endocrinology Diabetes and Hypertension, Oklahoma University Health Sciences Foundation, Oklahoma City, OK, USA
    • ,
  • W.Timothy Garvey

      Affiliations

    • Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA
    • Birmingham Veterans Affairs Medical Center, Birmingham, AL, USA

Received 3 September 2003 ,Revised 21 April 2004 ,Accepted 30 April 2004.

References 

  1. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, et al. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. Journal of Clinical Investigation. 1992;90:1889–1900
  2. Aalto-Setälä K, Kontula K, Sane T, Nieminen M, Nillila E. DNA polymorphisms of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease. Atherosclerosis. 1987;66:145–152
  3. Blankenhorn DH, Alaupovic P, Wichham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation. 1990;81:470–476
  4. Boyle KE, Phillips MC, Lund-Katz S. Kinetics and mechanism of exchange of apolipoprotein C-III molecules from very low density lipoprotein particles. Biochimica et Biophysica Acta. 1999;1430:302–312
  5. Breyer ED, Le NA, Li X, Martinson D, Brown WV. Apolipoprotein C-III displacement of apolipoprotein E from VLDL: effect of particle size. Journal of Lipid Research. 1999;40:1875–1882
  6. Chavers BM, Simonson J, Michael AF. A solid phase fluorescent immunoassay for the measurement of human urinary albumin. Kidney International. 1984;25:576–578
  7. Chen M, Breslow JL, Li W, Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. Journal of Lipid Research. 1994;35:1918–1924
  8. Dallongeville J, Meirhaeghe A, Cottel D, Fruchart JC, Amouyel P, Helbecque N. Gender associated association between genetic variations of APOC-III gene and lipid and lipoprotein variables in northern France. Arteriosclerosis. 2000;150:149–157
  9. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proceedings of the National Academy of Sciences, USA. 1993;90:4562–4566
  10. DCCT Research Group . The Diabetes Control and Complications Trial (DCCT). Design and methodologic considerations for the feasibility phase. Diabetes. 1986;35:530–545
  11. DCCT Research Group. (1993). DCCT manual of operations (Publ. No. 93-183382). Springfield, VA: National Technical Information Service.
  12. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Patients with nephrotic-range proteinuria have apolipoprotein C and E deficient VLDL 1. Kidney International. 2000;58:1238–1246
  13. Early Treatment Diabetic Retinopathy Study Research Group . Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report no. 12. Opthalmology. 1991;98:823–833
  14. Early Treatment Diabetic Retinopathy Study Research Group . Grading diabetic retinopathy from stereoscopic color fundus photographs—An extension of the modified Airlie House classification: ETDRS report no. 10. Opthalmology. 1991;98:786–806
  15. Ebara T, Ramakrishnan R, Steiner G, Shachter NS. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E null mice: Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E. Journal of Clinical Investigation. 1997;99:2672–2681
  16. EDIC Research Group . Epidemiology of diabetes interventions and complications (EDIC): design, implementation and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 1999;22:977–986
  17. Fredenrich A. Role of apolipoprotein CIII in triglyceride-rich lipoprotein metabolism. Diabetes Metab. 1998;24:490–495
  18. Gervaise N, Garrigue MA, Lasfargues G, Lecomte P. Triglycerides, apo C3, and LpB:C3 and cardiovascular risk in Type II diabetes. Diabetologia. 2000;43:703–708
  19. Groenendijk M, Cantor RM, Bloom NHHC, Rotter JI, de Bruin TWA, Dallinga-Thie GM. Association of plasma lipids and apolipoproteins with the insulin response element in the apoC-III promoter region in familial combined hyperlipidemia. Journal of Lipid Research. 1999;40:1036–1044
  20. Hedrick PW. Gametic disequilibrium measures: proceed with caution. Genetics. 1987;117:331–341
  21. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:2753–2758
  22. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, et al.  Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation. 1994;90:42–49
  23. Hoffer MJ, Sijbrands EJ, De Man FH, Havekes LM, Smelt AH, Frants RR. Increased risk for endogenous hypertriglyceridaemia is associated with an apolipoprotein C3 haplotype specified by the SstI polymorphism. European Journal of Clinical Investigation. 1998;28:807–812
  24. Jong MC, Hofker MH, Havekes LM. Role of apoCs in lipoprotein metabolism: functional differences between ApoC1, apoC2, and ApoC3. Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19:472–484
  25. Klein, R. L., Brent, M. M., Hunter, S. J., Le, N.-A., Jenkins, A. J., Zheng, D., Semler, A. J., Page, G., Brown, W. V., Lyons, T. J., Garvery, W. T., & the DCCT/EDIC Research Group. (in press). Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with lipoprotein subclasses. Metabolism.
  26. Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, et al.  Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 1996;122:105–115
  27. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Current Opinion in Lipidology. 1994;5:339–349
  28. Lamarche B, Moojani S, Lupien PJ, Cantin B, Bernard PM, Dagenais GR, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation. 1996;94:273–278
  29. Le N-A, Innis-Whitehouse W, Li X, Bakker-Arkema R, Black D, Brown WV. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reduction with atorvastatin. Metabolism. 2000;49:167–177
  30. Lee S-J, Campos H, Moye LA, Sacks FM. LDL containing apolipoprotein CIII is an independent risk factor for coronary events in diabetic patients. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:853–858
  31. Li WW, Dammennan MM, Smith JD, Metzger S, Breslow JL, Leff T. Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. Journal of Clinical Investigation. 1995;96:2601–2605
  32. Luc C, Fievet C, Arveiler D, Evans AE, Bard J-M, Cambien F, et al.  Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Journal of Lipid Research. 1996;37:508–517
  33. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. Journal of Biological Chemistry. 1994;269:23610–23616
  34. McConathy J, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang C-S. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. Journal of Lipid Research. 1992;33:995–1003
  35. Ordovas JM, Civeira F, Genest J, Craig S, Robbins AH, Meade T, et al.  Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis. 1991;87:75–86
  36. Ordovas JM, Schaefer EJ, Salem D, Ward RH, Glueck CJ, Vergani C, et al.  Apolipoprotein A-I gene polymorphism associated with premature coronary artery disease and familial hypoalphalipoproteinemia. New England Journal of Medicine. 1986;314:671–677
  37. Peacock RE, Temple A, Gudnason V, Rossenue M, Humphries SE. Variation at the lipoprotein lipase and apolipoprotein AI–CIII gene loci are associated with fasting lipid and lipoprotein traits in a population sample from Iceland: interaction between genotype, gender, and smoking status. Genetic Epidemiology. 1997;14:265–282
  38. Renard E, Dupuy AM, Momtier L, Crastes de Paulet A. DNA restriction polymorphisms of the apolipoprotein AI–CIII–AIV gene cluster: a genetic determinant of atherosclerosis in type 2 (non-insulin-dependent) diabetes mellitus. Diabetic Medicine. 1991;8:354–360
  39. Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, et al.  VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial. Circulation. 2000;102:1886–1892
  40. Schonfeld G, George PK, Miller J, Reilly P, Witzum J. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 1979;28:1001–1010
  41. Shachter NS. Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism. Current Opinion in Lipidology. 2001;12:297–304
  42. Shoulders CC, Grantham TT, North JD, Gaspardone A, Tomai F, De Fazio A, et al.  Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Human Genetics. 1996;98:557–566
  43. Stocks J, Paul H, Galton DJ. Haplotypes identified by DNA restriction-fragment-length polymorphisms in A-I/C-III/A-IV gene region and hypertriglyceridemia. American Journal of Human Genetics. 1987;41:106–118
  44. Surguchov AP, Page GP, Smith L, Patsch W, Boerwinkle E. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 1996;16:941–947
  45. Talmud PJ, Humphries SE. Apolipoprotein C-III gene variation and dyslipidemia. Current Opinion in Lipidology. 1997;8:154–158
  46. Terwilliger JD, Ott J. Handbook of genetic linkage. Baltimore, MD: Johns Hopkins Press; 1994;
  47. Wang C-S, McConathy J, Kloer HU, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein CIII. Journal of Clinical Investigation. 1985;75:384–390
  48. Wijsman EM, Brunzell JD, Jarvik GP, Austin MA, Motulsky AG, Deeb SS. Evidence against linkage of familial combined hyperlipidemia to the apolipoprotein AI–CIII–AIV gene complex. Arteriosclerosis, Thrombosis, and Vascular Biology. 1998;18:215–226
  49. Wile DB, Barbir M, Gallagher J, Myant NB, Ritchie CD, Thompson GR. Apolipoprotein A-I gene polymorphisms: frequency in patients with coronary artery disease and healthy controls and association with serum apo A-I and HDL-cholesterol concentration. Atherosclerosis. 1989;78:9–18

PII: S1056-8727(04)00053-4

doi: 10.1016/j.jdiacomp.2004.04.005

Journal of Diabetes and Its Complications
Volume 19, Issue 1 , Pages 18-25 , January 2005

Article Tools

* Image Usage & Resolution